SWP
VRTX icon

ShoreHaven Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

ShoreHaven Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50
Closed -$11K – 248
2021
Q1 		$11K Hold
50
– – 0.01% 197
2020
Q4 		$12K Buy
+50
New +$11.5K 0.01% 167

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ShoreHaven Wealth Partners's VRTX Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 50 shares — an estimated $11K sold.

ShoreHaven Wealth Partners first reported a position in VRTX in Q4 2020 and held it in 2 quarters. The position peaked at $12K in Q4 2020. 978 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

  • ShoreHaven Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • ShoreHaven Wealth Partners sold 50 Vertex Pharmaceuticals shares in Q2 2021, an estimated $11K.
  • ShoreHaven Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • ShoreHaven Wealth Partners's Vertex Pharmaceuticals position peaked at $12K in Q4 2020.
  • 978 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.